Clinical Trials Sponsored by Bader Philanthropies

Total 2533 results

Bayer

Completed

Sun Protection Factor Assay (SPF Assay)

Sunscreening Agent

United States
Bayer

Completed

A Multi-Site Evaluation of the Pain Relief, Support, Fit and Comfort From Use of a Custom Knee or Ankle Brace in Persons Suffering From Chronic Ankle or Knee Pain and Instability

Joint Instability

United States
Bayer

Completed

18615 - Sun Protection Factor Assay (SPF Assay)

Sunscreening Agent

United States
Bayer

Completed

18613 - Sun Protection Factor Assay (SPF Assay)

Sunscreening Agent

United States
Bayer

Completed

To Test for Photo Allergy Reaction of Sunscreens

Photoallergy

United States
Bayer

Completed

18519 - Sun Protection Factor Assay (SPF Assay)

Sunscreening Agent

United States
Bayer

Completed

Sun Protection Factor (SPF) Efficacy Assay

Sunscreen Agents

United States
Bayer

Completed

Sun Protection Factor Assay (SPF Assay)

Sunscreening Agent

United States
Bayer

Completed

18432-Sun Protection Factor Assay (SPF Assay)

Sunscreening Agent

United States
Bayer

Completed

18572 - Sun Protection Factor Assay (SPF Assay)

Sunscreening Agent

United States
Bayer

Completed

An Evaluation of a Gender Specific Insole to Provide Relief From Knee Pain Due to Osteoarthritis or General Anterior Knee Pain in Male Subjects When Used in Foot Wear Over a Period of Four Weeks

Osteoarthritis, Knee

United States
Bayer

Completed

Outcomes of HCC (Hepatocellular Carcinoma) Patients Treated With TACE (Transarterial Chemoembolization) and Early, Not Early or Not at All Followed by Sorafenib (OPTIMIS)

Carcinoma, Hepatocellular

Japan, Turkey, Austria, Czechia, Hungary, Israel, Russian Federation, Slovakia, Switzerland, India, Korea, Republic of, France, Mexico, Indonesia, Singapore, Thailand, Canada, Greece, Netherlands, Spain, Taiwan, Poland, Brazil, China, D... and more
Bayer

Completed

BAY86-9766 Plus Gemcitabine Phase I Study in Asian

Neoplasms

China, Korea, Republic of, Japan
Bayer

Completed

Safety and Efficacy of BAY1192631 in Japanese Patients With Methicillin-resistant Staphylococcus Aureus (MRSA) Infections

Skin Diseases, Infectious

Japan
Bayer

Completed

A Non-interventional Study to Observe the Computed Tomographic Angiography Image Quality With Different Contrast Media Injection Protocols Under Different Computed Tomography Machines Parameters Setting (RIGHT)

Multidetector Computed Tomography | Angiography

China
Bayer

Completed

Study Comparing PEG 3350 Laxative to Placebo in the Treatment of Occasional Constipation (Study CL2007-12)(P08216)

Constipation
Bayer

Completed

Comparative PK PD Study in PAH Patients (Fox vs. I-Neb)

Pulmonary Arterial Hypertension

Germany, Austria
Bayer

Completed

Treatment Patterns in Castrate Resistant Prostate Cancer Patients With Bone Metastases in a Medicare Population

Prostate Cancer

United States
Bayer

Completed

A Manufacturing Transfer Study Comparing the Bioequivalence of a Single Oral Dose of Claritin-D 12-Hour Extended Release Tablet From 2 Different Manufactuers Under Fed Conditions in Healthy Adult Subjects

Clinical Pharmacology

United States
Bayer

Completed

Trial to Evaluate the Pharmacokinetics and Safety Profile of BAY94-9027 Following Single and Multiple Dose Administration

Hemophilia A

United States
Bayer

Completed

Regulatory Post Marketing Surveillance Study in Korea

Endometriosis

Korea, Republic of
Bayer

Completed

Nexavar Post-marketing Surveillance for RCC in Japan: Early Access Program

Carcinoma, Renal Cell

Japan
Bayer

Completed

Phase I Dose Escalation Study of BAY94-9343 Given by Intravenous Infusion Every 3 Weeks in Japanese Subjects With Advanced Malignancies

Neoplasms

Japan
Bayer

Completed

Special Drug Use Investigation - Assessment of Efficacy and Safety in Treating Secondary Infection of Chronic Respiratory Disease

Anti-Infective Agents

Japan
Bayer

Terminated

Single Ascending Dose, First-in-Human Study on Safety, Tolerability and Pharmacokinetics of BAY1161116

Polycystic Ovary Syndrome

Germany
Bayer

Completed

Gadobutrol/Gadavist-enhanced Cardiac Magnetic Resonance Imaging (CMRI) to Detect Coronary Artery Disease (CAD) (GadaCAD 1)

Coronary Artery Disease

New Zealand, United Kingdom, United States, France, Germany, Korea, Republic of, Switzerland
Bayer

Completed

Metastatic Colorectal Cancer Patients With Long-term Response to Regorafenib (COLONG)

Colorectal Neoplasms

Belgium
Bayer

Completed

Phase I Dose Escalation Study of BAY 1163877 (Rogaratinib) in Japanese Subjects With Refractory, Locally Advanced or Metastatic Solid Tumors

Neoplasms

Japan
Bayer

Completed

Noninterventional Study Assessing Cognitive Function and Physical Activity in People With Multiple Sclerosis (CogniPlus)

Multiple Sclerosis

Turkey, Czechia, Hungary, Israel, Germany, France, Belgium, Greece, Netherlands, Egypt, Kazakhstan, Argentina, Portugal, Algeria, Saudi Arabia, Albania, Tunisia
Bayer

Completed

Sun Protection Factor Assay (316/2016) (SPF Assay)

Sunscreening Agents

United States
Bayer

Completed

Sun Protection Factor Assay (341/2016)

Sunscreening Agents

United States
Bayer

Completed

Incidence of Second Primary Malignancies in Prostate Cancer Patients With Bone Metastases - an Observational Retrospective Cohort Study in Sweden (SMARCOS)

Prostatic Neoplasms

Sweden
Bayer

Completed

Atrial Fibrillation Patient Preference Study (PRiSMA-AF)

Atrial Fibrillation

Sweden
Bayer

Completed

Exit Interviews to Assess Impact of Infusion Frequency in Hemophilia A

Hemophilia A

United States
Bayer

Completed

Treatment Patterns in Metastatic Prostate Cancer

Prostatic Neoplasm

United States
Bayer

Completed

Sorafenib Concomitantly Used With TACE (Transarterial Chemoembolization) in uHCC (Unresectable Hepatocellular Carcinoma) Patients in China (SUCCESS)

Carcinoma, Hepatocellular

China
Bayer

Completed

Evaluation of a Gel Sunscreen in Controlled Use Conditions (208/2016)

Sunscreening Agents

United States
Bayer

Completed

Sun Protection Factor Assay (339/2016)

Sunscreening Agents

United States
Bayer

Completed

Observational Description of Compliance for the Daily Ventavis Use Via the Insight Program in Class III Pulmonary Arterial Hypertension Patients (DAILY)

Pulmonary Arterial Hypertension

France
Bayer

Terminated

Efficacy and Safety of Riociguat in Patients With Symptomatic Pulmonary Hypertension (PH) Associated With Idiopathic Interstitial Pneumonias (IIP) (RISE-IIP)

Idiopathic Interstitial Pneumonias / Hypertension,Pulmonary

Belgium, Israel, Spain, United States, Switzerland, New Zealand, Greece, Portugal, Japan, Argentina, Canada, Denmark, France, Germany, Russian Federation, Turkey, Colombia, Saudi Arabia, Australia, Italy, United Kingdom
Bayer

Completed

Long-term Pre-dialysis Extension in Europe and Asia Pacific (DIALOGUE 3)

Renal Insufficiency, Chronic | Anemia

United Kingdom, France, Spain, Japan, Hungary, Korea, Republic of, Israel, Italy, Bulgaria, Australia, Germany, Poland, Romania, Turkey
Bayer

Completed

Open Label Phase I Dose Escalation Study With BAY1143572 in Patients With Advanced Cancer

Neoplasms

Singapore, United States, Korea, Republic of, Taiwan
Bayer

Terminated

A Phase 4 Study of Regorafenib in Metastatic Colorectal Cancer - Does Educating Physicians Change Patient Outcomes? (SMART)

Physician Education

United States
Bayer

Completed

BAY80-6946 Open Label, Phase I Study in Patients With Advanced Cancer

Neoplasms

United States
Bayer

Completed

Phase 1 Study of PI3 (Phosphatidylinositol-3)-Kinase Inhibitor Copanlisib With Gemcitabine or Cisplatin Plus Gemcitabine in Patients With Advanced Cancer

Neoplasms

United States
Bayer

Completed

Anticoagulation Preference by AF Patients Study (PRiSMA-AF)

Atrial Fibrillation

Switzerland
Bayer

Completed

Russia/Ukraine Suppression of Ovarian Activity Study

Contraception

Russian Federation, Ukraine
Bayer

Completed

Effect of Concomitant Use of an Antimycotic, an Antibiotic, a Spermicide or Tampons on Pharmacokinetics of Anastrozole and Levonorgestrel Released From Intra-vaginal Ring

Endometriosis

Germany
Bayer

Completed

Study Evaluating Betaferons Safety and Tolerability In Pediatric Patients With Multiple Sclerosis

Multiple Sclerosis

Germany, Austria, United Kingdom, Israel, Belgium, Finland
Bayer

Completed

An Observational Study to Assess Quality of Life and Satisfaction of Young Women (Aged 18-29) Following 6 (±1) Months Using Jaydess as Their Contraceptive Method (JULIA)

Quality of Life

Spain

3

Subscribe